Bionorica 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
3 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dronabinol (BX-1) / Bionorica
2019-000616-28: Study to investigate the efficacy and safety of dronabinol in the improvement of chemotherapy-induced and tumor-related symptoms in patients with advanced pancreatic cancer during first-line chemotherapy Studie zur Untersuchung der Wirksamkeit und Sicherheit von Dronabinol bei der Besserung von Chemotherapie- und Tumor-bedingten Symptomen bei Patienten mit lokal fortgeschrittenem oder metastasiertem Pankreaskarzinom während der Erstlinientherapie

Not yet recruiting
3
104
Europe
BX-1, Oral solution
AGMT gGmbH, Bionorica SE
Advanced pancreatic (locally advanced, inoperable or metastatic) cancer during first-line chemotherapy Lokal fortgeschrittenes, inoperables oder metastasiertes Pankreaskarzinom während der Erstlinientherapie, Advanced pancreatic (locally advanced, inoperable or metastatic) cancer during first-line chemotherapy Lokal fortgeschrittenes, inoperables oder metastasiertes Pankreaskarzinom während der Erstlinientherapie, Diseases [C] - Cancer [C04]
 
 
DIsCOvER, NCT03984214: Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer

Completed
3
109
Europe
Dronabinol in Oral Dosage Form, BX-1, Placebo in Oral Dosage Form
Arbeitsgemeinschaft medikamentoese Tumortherapie, Medical University of Graz, Unidata Geodesign, Bionorica SE
Pancreatic Cancer Non-resectable, Chemotherapy-induced Nausea and Vomiting, Pancreatic Cancer Metastatic
09/24
09/24
NCT04448808: Treating Nightmares in Posttraumatic Stress Disorder with Dronabinol

Active, not recruiting
2
176
Europe
BX-1, Placebo
Charite University, Berlin, Germany, Bionorica SE
Posttraumatic Stress Disorder
01/25
06/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dronabinol (BX-1) / Bionorica
2019-000616-28: Study to investigate the efficacy and safety of dronabinol in the improvement of chemotherapy-induced and tumor-related symptoms in patients with advanced pancreatic cancer during first-line chemotherapy Studie zur Untersuchung der Wirksamkeit und Sicherheit von Dronabinol bei der Besserung von Chemotherapie- und Tumor-bedingten Symptomen bei Patienten mit lokal fortgeschrittenem oder metastasiertem Pankreaskarzinom während der Erstlinientherapie

Not yet recruiting
3
104
Europe
BX-1, Oral solution
AGMT gGmbH, Bionorica SE
Advanced pancreatic (locally advanced, inoperable or metastatic) cancer during first-line chemotherapy Lokal fortgeschrittenes, inoperables oder metastasiertes Pankreaskarzinom während der Erstlinientherapie, Advanced pancreatic (locally advanced, inoperable or metastatic) cancer during first-line chemotherapy Lokal fortgeschrittenes, inoperables oder metastasiertes Pankreaskarzinom während der Erstlinientherapie, Diseases [C] - Cancer [C04]
 
 
DIsCOvER, NCT03984214: Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer

Completed
3
109
Europe
Dronabinol in Oral Dosage Form, BX-1, Placebo in Oral Dosage Form
Arbeitsgemeinschaft medikamentoese Tumortherapie, Medical University of Graz, Unidata Geodesign, Bionorica SE
Pancreatic Cancer Non-resectable, Chemotherapy-induced Nausea and Vomiting, Pancreatic Cancer Metastatic
09/24
09/24
NCT04448808: Treating Nightmares in Posttraumatic Stress Disorder with Dronabinol

Active, not recruiting
2
176
Europe
BX-1, Placebo
Charite University, Berlin, Germany, Bionorica SE
Posttraumatic Stress Disorder
01/25
06/25

Download Options